Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the PARADIGM Trial)
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) --…
Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib…
33 year old driver from Tripura treated with Eastern India’s first-ever Bachmann’s Bundle Pacing
KOLKATA, India, June 27, 2025 /PRNewswire/ -- In a landmark achievement that…
